X

Trial Profile

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Allergic asthma; Asthma
Focus Therapeutic Use

Most Recent Events

13 Sep 2023 Results investigating cytokines associated with residual symptoms post-benralizumab by assessing sputum collected at baseline (V1), after placebo(V3), and 5 injections of benralizumab , presented at the 33rd Annual Congress of the European Respiratory Society
18 Jan 2023 Status changed from recruiting to completed.
06 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com